Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors

On January 31, 2012, the U.S. Food and Drug Administration granted regular approval of imatinib mesylate tablets (Gleevec®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) for the adjuvant treatment of adult patients following complete gross resection of Kit(+) (CD117(+)) gastrointestinal st...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Cohen, Martin H., Johnson, John R., Justice, Robert, Pazdur, Richard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2012
Gaiak:
Regulatory Issues: FDA
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399657/
https://ncbi.nlm.nih.gov/pubmed/22643537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0109
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak